Related Resources for this page:
- Tumor Types
- Biological Pathways
- Pipeline Molecules
- Research Education
- ResearchBRAF
- ResearchBcell
- ResearchHERPathways
- ResearchVEGF
- Angiogenesis is essential to tumor development
- Biology of RCC
- Glossary
- A detailed look at the VEGF pathway
- Glioblastomas, angiogenesis, and VEGF
- Postreceptor signaling
- Research VEGF
- The role of ubiquitination
- Unique role of VEGF in RCC pathogenesis
- The VEGF ligand and angiogenesis
- Why is the VEGF ligand essential throughout tumor development?
- Growth and survival of tumor blood vessels
- Why do tumors progress?
- Slide decks and videos
- Evidence of VEGF expression
- VEGF expression/angiogenic switch
- What are the strategies for inhibiting the VEGF pathway?
- VEGF ligands and receptors
- The angiogenic process
- VEGF: a predominant mediator of angiogenesis
- Clinical Trials
- Cancer Biomarkers
- Future Directions
- Antibody-Drug Conjugates
- A brief history of ADCs
- Current research in ADCs
- Cytotoxic agent
- Emerging therapeutic options
- Emerging therapeutic options
- HER Signaling
- How are ADCs designed to work?
- Hypoxic tumor environment promotes angiogenesis
- Glossary
- Monoclonal antibody
- Regulation of VEGF expression
- Research ADCs
- Serum VEGF as a clinical marker
- Slide decks and videos
- Stable linker
- Summary
- Summary
- Targeting cancers with ADCs
- VEGF in gastric cancer
- VEGF in pancreatic cancer
- VEGF and prognosis in pancreatic cancer
- VEGF and tumor progression in gastric cancer
- VEGF and tumor progression in pancreatic cancer
- VEGF expression and liver metastases
- VEGF expression in gastric cancer
- VEGF, MVD, and metastases in gastric carcinoma
- What are ADCs?
- Antibody-Drug conjugates
- Bispecific Monoclonal Antibodies
- Glycoengineered Antibodies
- Emerging therapeutic options
- Emerging therapeutic options
- HER Signaling
- Hypoxic tumor environment promotes angiogenesis
- Obinutuzumab (GA101)
- Regulation of VEGF expression
- Serum VEGF as a clinical marker
- Summary
- Summary
- VEGF in gastric cancer
- VEGF in pancreatic cancer
- VEGF and prognosis in pancreatic cancer
- VEGF and tumor progression in gastric cancer
- VEGF and tumor progression in pancreatic cancer
- VEGF expression and liver metastases
- VEGF expression in gastric cancer
- VEGF, MVD, and metastases in gastric carcinoma
- Non-Antibody Biologics
- Apoptosis
- Hypoxic tumor environment promotes angiogenesis
- Regulation of VEGF expression
- Serum VEGF as a clinical marker
- Summary
- Summary
- What are the strategies for inhibiting the VEGF pathway?
- VEGF in gastric cancer
- VEGF in pancreatic cancer
- VEGF and prognosis in pancreatic cancer
- VEGF and tumor progression in gastric cancer
- VEGF and tumor progression in pancreatic cancer
- VEGF expression and liver metastases
- VEGF expression in gastric cancer
- VEGF, MVD, and metastases in gastric carcinoma
- Targeted Small Molecules
- Apoptosis
- Emerging therapeutic options
- Emerging therapeutic options
- Resisting apoptosis
- Gastric Cancer
- HER1/EGFR as a therapeutic target
- Hypoxic tumor environment promotes angiogenesis
- MAPK Signaling
- MEK Inhibitor (GDC-0973)
- Melanoma
- Regulation of VEGF expression
- Serum VEGF as a clinical marker
- Summary
- Summary
- PI3K/Akt/mTOR Signaling
- Therapeutic potential of HER pathways
- Slide decks and videos
- What are the strategies for inhibiting the VEGF pathway?
- VEGF in gastric cancer
- VEGF in pancreatic cancer
- VEGF and prognosis in pancreatic cancer
- VEGF and tumor progression in gastric cancer
- VEGF and tumor progression in pancreatic cancer
- VEGF expression and liver metastases
- VEGF expression in gastric cancer
- VEGF, MVD, and metastases in gastric carcinoma
- Traditional Monoclonal Antibodies
- Anti-EGFL7
- Glossary
- Emerging therapeutic options
- Emerging therapeutic options
- Gastric Cancer
- HER Signaling
- HER1/EGFR as a therapeutic target
- HER2:HER3 dimer
- HER2 as a therapeutic target
- HER3 as a therapeutic target
- Hypoxic tumor environment promotes angiogenesis
- Melanoma
- Obinutuzumab (GA101)
- Regulation of VEGF expression
- Serum VEGF as a clinical marker
- Summary
- Summary
- Therapeutic potential of HER pathways
- Slide decks and videos
- What are the strategies for inhibiting the VEGF pathway?
- VEGF in gastric cancer
- VEGF in pancreatic cancer
- VEGF and prognosis in pancreatic cancer
- VEGF and tumor progression in gastric cancer
- VEGF and tumor progression in pancreatic cancer
- VEGF expression and liver metastases
- VEGF expression in gastric cancer
- VEGF, MVD, and metastases in gastric carcinoma
- Antibody-Drug Conjugates
Targeting angiogenesis:
Inhibition of a tumor’s lifeline
Angiogenesis is a vital process that facilitates tumor growth and survival.1-3 Tumor angiogenesis refers to the ability of a tumor to stimulate new blood vessel formation.1,2 This critical step in development enables tumor expansion, local invasion, and dissemination through1-3:
- Delivery of oxygen, nutrients, and survival factors
- Production of growth factors that benefit tumor cells
- Formation of a route for tumor cell egress
Angiogenesis is a well-controlled process that is regulated by angiogenic, growth, and survival factors that are secreted by the malignant cells as well as other cells within the tumor microenvironment.2,4
The process of sprouting angiogenesis is regulated by many extracellular factors, including EGF-like domain-containing protein 7 (EGFL7), a protein expressed by endothelial cells.5-8 EGFL7 is associated with the extracellular matrix and is upregulated in many proliferative tissues, including tumors.6-8 EGFL7 supports endothelial cell adhesion and vascular tube formation by defining an efficient migratory path for endothelial cells.8 Furthermore, it also protects endothelial cells that are under biological stress, another pro-survival mechanism.9
References:
- 1.
- Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57-70.
- 2.
- Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 2003;3:401-410.
- 3.
- Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005;23:1011-1027.
- 4.
- Nyberg P, Salo T, Kalluri R. Tumor microenvironment and angiogenesis. Front Biosci. 2008;13:6537-6553.
- 5.
- Schmidt M, Paes K, De Mazière A, et al. EGFL7 regulates the collective migration of endothelial cells by restricting their spatial distribution. Development. 2007;134:2913-2923.
- 6.
- Campagnolo L, Leahy A, Chitnis S, et al. EGFL7 is a chemoattractant for endothelial cells and is up-regulated in angiogenesis and arterial injury. Am J Pathol. 2005;167:275-284.
- 7.
- Fitch MJ, Campagnolo L, Kuhnert F, Stuhlmann H. Egfl7, a novel epidermal growth factor-domain gene expressed in endothelial cells. Dev Dyn. 2004;230:316-324.
- 8.
- Parker LH, Schmidt M, Jin S-W, et al. The endothelial-cell-derived secreted factor Egfl7 regulates vascular tube formation. Nature. 2004;428:754-758.
- 9.
- Xu D, Perez RE, Ekekezie II, Navarro A, Truog WE. Epidermal growth factor-like domain 7 protects endothelial cells from hyperoxia-induced cell death. Am J Physiol Lung Cell Mol Physiol. 2008;294:L17-L23.